13F Holdings
中文EN

MDGL MADRIGAL PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1157601 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY92.8%
TTM net income YoY46.2%
TTM EPS YoY24.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-10.7%
Net margin-10.9%
FCF margin-11.8%
EBITDA margin-10.6%

Returns

ROE-24.8%
ROA-11.1%
ROIC (approx.)-21.6%
Asset turnover1.02x

Leverage & solvency

Liabilities / assets56.3%
Debt / equity0.54x
Current ratio3.05x
Interest coverage-4.75x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$958.40M$180.13M$0$0$0
Cost of revenue—$6.23M$0$0—
Gross profit—$173.90M$0$0—
R&D expense$388.52M$236.72M$272.35M$245.44M$205.16M
SG&A expense$813.83M$435.06M$108.15M$48.13M$37.32M
Operating income-$300.10M-$497.88M-$380.50M-$293.57M-$242.48M
Interest expense$22.31M$14.67M$12.71M$3.96M$0
Pretax income-$158.50M-$465.90M-$373.60M——
Income tax$0$0$0$0$0
Net income-$288.28M-$465.89M-$373.63M-$295.35M-$241.85M
EBITDA-$298.59M-$496.78M-$379.97M-$293.10M-$242.08M
EPS (basic)-12.85-21.90-19.99-17.23-14.63
EPS (diluted)-12.85-21.90-19.99-17.23-14.63
Weighted avg. shares (diluted)22.43M21.27M18.69M17.14M16.54M
Balance sheet
Cash & equivalents$198.69M$105.02M$99.92M$331.55M$36.27M
Short-term investments$784.87M$826.23M$534.22M$27.23M$234.08M
Receivables$134.48M$53.82M$0——
Inventory$74.84M$34.07M$0——
Current assets$1.25B$1.03B$637.28M$361.37M$271.68M
PP&E, net$1.50M$2.19M$1.55M$601,000$851,000
Intangibles$7.38M$4.73M$0——
Total assets$1.26B$1.04B$640.55M$362.57M$273.33M
Current liabilities$310.29M$169.28M$118.55M$115.89M$76.84M
Long-term debt$339.88M$117.57M$115.48M$49.29M$0
Total debt$339.88M$117.57M$115.48M$49.29M$0
Total liabilities$656.90M$287.86M$235.21M$165.18M$77.22M
Shareholders' equity$602.69M$754.38M$405.33M$197.39M$196.11M
Net debt$141.19M$12.55M$15.56M-$282.26M-$36.27M
Shares outstanding22.84M22.00M19.88M18.10M17.10M
Cash flow statement
Operating cash flow-$189.55M-$455.57M-$324.23M-$224.86M-$183.92M
Capital expenditure$467,000$1.46M$1.48M$217,000$209,000
Free cash flow-$190.02M-$457.03M-$325.71M-$225.07M-$184.13M
Investing cash flow$32.32M-$274.39M-$502.52M$206.69M-$5.05M
Financing cash flow$255.98M$735.06M$595.12M$313.45M$171.24M
Depreciation & amortization$1.51M$1.10M$527,000$467,000$405,000
Stock-based compensation$98.13M$79.88M$49.73M$31.62M$26.87M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.